Ionis director Hayden's spouse buys 5,000 shares

Available on EDGAR 11/13/2026 - 04:20 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:19 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals Inc. (IONS) director Michael R. Hayden reported that his spouse purchased 5,000 common shares indirectly on November 10, 2026, at a weighted-average price of $29.64 per share; the transactions ranged from $29.60 to $29.68. Reported indirect holdings after the purchase were 27,000 shares, and direct holdings were 54,298 shares. A footnote says indirect holdings as of July 31, 2026, were 22,000 shares, rather than the 24,000 previously reported. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Hayden Michael R

Role Director

Bought 5,000 shs ($148K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	5,000	$29.64	$148K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,000 shares (Indirect, by Spouse); Common Stock — 54,298 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.60 to $29.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.
2. F2. The number of securities indirectly owned by the reporting person was reported as 24,000 shares on the Form 4 filed July 31, 2026. The correct number of securities indirectly owned by the reporting person as of July 31, 2026, was 22,000 shares. The amount reported on this Form 4 reflects the reporting person's correct indirect beneficial ownership.

Key Figures

Shares purchased: 5,000 shares Weighted-average purchase price: $29.64 per share Purchase price range: $29.60–$29.68 per share +3 more

6 metrics

Shares purchased 5,000 shares Indirect purchase by the director's spouse on November 10, 2026

Weighted-average purchase price $29.64 per share Purchase on November 10, 2026

Purchase price range $29.60–$29.68 per share Multiple transactions on November 10, 2026

Indirect holdings after purchase 27,000 shares Reported following the November 10, 2026 purchase

Direct holdings 54,298 shares Reported on November 10, 2026

Corrected indirect holdings 22,000 shares As of July 31, 2026; 24,000 shares had been reported previously

Key Terms

weighted average price, indirect beneficial ownership

2 terms

weighted average price financial

"The price reported was a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect beneficial ownership financial

"The amount reflects the reporting person's correct indirect beneficial ownership"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IONS shares did Michael R. Hayden's spouse buy, and at what price?

Michael R. Hayden's spouse purchased 5,000 common shares on November 10, 2026, at a weighted-average price of $29.64 per share. The separate transaction prices ranged from $29.60 to $29.68.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hayden Michael R

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2026		P		5,000	A	$29.64(1)	27,000(2)	I	by Spouse
Common Stock								54,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.60 to $29.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.

2. The number of securities indirectly owned by the reporting person was reported as 24,000 shares on the Form 4 filed July 31, 2026. The correct number of securities indirectly owned by the reporting person as of July 31, 2026, was 22,000 shares. The amount reported on this Form 4 reflects the reporting person's correct indirect beneficial ownership.

	By: Patrick R. O'Neil, attorney-in-fact For: Michael R. Hayden	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)